AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Allogeneic melanoma tumor cell lysate vaccine benefits patients.
2004 FEB 11 - (NewsRx.com & NewsRx.net) -- The allogeneic melanoma tumor cell lysate vaccine Melacine appears to benefit patients in clinical trials.
"The identification of proteins and carbohydrates associated with melanoma led to development of defined antigen vaccines. However, vaccines derived from whole allogeneic cells have a number of advantages. Melacine is an allogeneic melanoma tumor cell lysate combined with an immunologic adjuvant, DETOX," investigators in the United States report.
"Phase I and II trials in stage IV melanoma showed low-level antitumor activity, but this vaccine has its greatest promise in the adjuvant setting," said Vernon K. Sondak at the University of Michigan Jeffrey A. Sosman at Vanderbilt University. "A phase III trial indicated a survival benefit for Melacine in the subset of melanoma patients who express the HLA class I antigens A2 and/or HLA-C3. This finding must now be prospectively confirmed."
...
- Allogeneic melanoma tumor cell lysate vaccine benefits patients.
- Newspaper article from: Cancer Weekly February 10, 2004 700+ words
...NewsRx.net) -- The allogeneic melanoma tumor cell lysate vaccine Melacine...advantages. Melacine is an allogeneic melanoma tumor cell lysate combined with...clinical trials with an allogeneic melanoma tumor cell lysate vaccine...
- Dendritic cells loaded with killed allogeneic melanoma cells can induce...
- Magazine article from: Baylor University Medical Center Proceedings Palucka, A.K. Ueno, H. Connolly, J. Kerneis-Norvell, F. Blanck, J.P. Johnston, D.A. Fay, J. Banchereau, J. January 1, 2007 700+ words
J Immunother 2006;29(5):545-557. Reproduced with permission from Lippincott Williams & Wilkins. Dendritic cells (DCs) loaded with killed allogeneic tumors can cross-prime tumor-specific naive CD[8.sup T cells in vitro, thereby providing an option to overcome human leukocyte antigen restriction
- Treatment for Cutaneous Melanoma Tumor Nodules.(Clinical report)
- Newspaper article from: Clinical Oncology Alert June 1, 2000 700+ words
Treatment for Cutaneous Melanoma Tumor Nodules ABSTRACT & COMMENTARY...cisplatin administration for melanoma tumor nodules. An objective response...administration into cutaneous melanoma tumor nodules. A total of 133 tumor...
- SciClone Announces its SCV-07 Inhibits Melanoma Tumor Growth in Animal Model...
- Press release article from: M2 Presswire June 4, 2007 700+ words
...Headline Maker: SciClone Announces its SCV-07 Inhibits Melanoma Tumor Growth in Animal Model Study(C)1994-2007 M2 COMMUNICATIONS...Animal Model Data In this study, mice inoculated with melanoma tumor were randomized into six treatment groups: four which received...
- Ribi ImmunoChem receives FDA allowance for testing of melanoma tumor vaccine....
- Press release article from: PR Newswire October 11, 1988 700+ words
...IMMUNOCHEM RECEIVES FDA ALLOWANCE FOR TESTING OF MELANOMA TUMOR VACCINE HAMILTON, Mont., Oct. 11 /PRNewswire...Administration (FDA) to begin clinical testing of its melanoma tumor vaccine which will now be manufactured in its newly...
- Proteasomal targeting improves presentation of melanoma tumor antigen.
- Newspaper article from: Immunotherapy Weekly April 21, 2004 700+ words
...net) -- Proteasomal targeting and minigene repetition improve cell-surface presentation of a transfected, modified melanoma tumor antigen. "Melanoma antigen recognized by T cell 1 (MART-1) is regarded as a candidate peptide for vaccination against...
- Lorus Therapeutics' Anti Cancer Drug NC 381 Inhibits The Spread Of Human...
- Press release article from: Business Wire February 7, 2000 700+ words
...has determined that its key anti-cancer drug NC 381 showed positive pre-clinical results in preventing the spread of melanoma tumor cells in experiments using mice containing human tumor cells. Under the direction of Dr. Changnian Liu of the University...
- New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced...
- Press release article from: PR Newswire April 7, 2008 700+ words
...shaved skin of a different group of mice. After seven days of treatment, all of the mice were injected with malignant melanoma tumor cells. Dermytol(TM) or placebo treatments continued for 25 days. The mice in both Dermytol(TM) groups benefited...
Source: HighBeam Research, Allogeneic melanoma tumor cell lysate vaccine benefits patients.